From salvage to spotlight: how 2025 transformed PSMA radioligand therapy
- Author(s)
- Al-Khanaty, A; Delgado, C; Valencia, F; Chen, D; Perera, ML; Eapen, R; Azad, AA; Buteau, JP; Hofman, MS; Murphy, DG;
- Journal Title
- BJU International
- Publication Type
- Online publication before print
- Keywords
- lutetium 177; precision oncology; prostate cancer; prostate cancer theranostics; prostate‐specific membrane antigen radioligand therapy; radiopharmaceutal therapy; terbium 161; treatment intensification
- Department(s)
- Surgical Oncology; Cancer Imaging; Medical Oncology
- Publisher's Version
- https://doi.org/10.1111/bju.70282
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-04-28 11:41:18
Last Modified: 2026-04-28 11:41:44